Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

BACKGROUND: The NAPOLI-1 trial demonstrated that liposomal irinotecan in combination with fluorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Front Oncol
मुख्य लेखकों: Yu, Kenneth H., Hendifar, Andrew E., Alese, Olatunji B., Draper, Amber, Abdelrahim, Maen, Burns, Ethan, Khan, Gazala, Cockrum, Paul, Bhak, Rachel H., Nguyen, Catherine, DerSarkissian, Maral, Duh, Mei Sheng, Bahary, Nathan
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Frontiers Media S.A. 2021
विषय:
Oncology
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8319949/
https://ncbi.nlm.nih.gov/pubmed/34336666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.678070
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन